To establish the pivotal role of universal neratinib in enhancing the effectiveness of CDK4/6 inhibitor combined with endocrine therapy in HR+/HER2-low breast cancer via HER2 pathway inhibition, HER2 was stably knocked down in human HR+/HER2-low breast cancer cells. This evidence concerns the gene CDK4 and breast carcinoma.